16-79598568-G-A
Variant names:
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_005360.5(MAF):c.1118+217C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.27 in 1,435,962 control chromosomes in the GnomAD database, including 53,828 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.27 ( 5470 hom., cov: 26)
Exomes 𝑓: 0.27 ( 48358 hom. )
Consequence
MAF
NM_005360.5 intron
NM_005360.5 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -1.13
Publications
5 publications found
Genes affected
MAF (HGNC:6776): (MAF bZIP transcription factor) The protein encoded by this gene is a DNA-binding, leucine zipper-containing transcription factor that acts as a homodimer or as a heterodimer. Depending on the binding site and binding partner, the encoded protein can be a transcriptional activator or repressor. This protein plays a role in the regulation of several cellular processes, including embryonic lens fiber cell development, increased T-cell susceptibility to apoptosis, and chondrocyte terminal differentiation. Defects in this gene are a cause of juvenile-onset pulverulent cataract as well as congenital cerulean cataract 4 (CCA4). Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2010]
MAF Gene-Disease associations (from GenCC):
- Ayme-Gripp syndromeInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
- cataract 21 multiple typesInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Ambry Genetics
- cataract - microcornea syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- cerulean cataractInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- pulverulent cataractInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fine-Lubinsky syndromeInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.83).
BP6
Variant 16-79598568-G-A is Benign according to our data. Variant chr16-79598568-G-A is described in ClinVar as [Benign]. Clinvar id is 1291603.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.275 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MAF | ENST00000326043.5 | c.1118+217C>T | intron_variant | Intron 1 of 1 | 1 | NM_005360.5 | ENSP00000327048.4 | |||
MAF | ENST00000393350.1 | c.*213C>T | 3_prime_UTR_variant | Exon 1 of 1 | 6 | ENSP00000377019.1 | ||||
MAF | ENST00000569649.1 | c.1118+217C>T | intron_variant | Intron 1 of 1 | 5 | ENSP00000455097.1 |
Frequencies
GnomAD3 genomes AF: 0.269 AC: 39266AN: 146156Hom.: 5461 Cov.: 26 show subpopulations
GnomAD3 genomes
AF:
AC:
39266
AN:
146156
Hom.:
Cov.:
26
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.270 AC: 348862AN: 1289698Hom.: 48358 Cov.: 57 AF XY: 0.270 AC XY: 169166AN XY: 625772 show subpopulations
GnomAD4 exome
AF:
AC:
348862
AN:
1289698
Hom.:
Cov.:
57
AF XY:
AC XY:
169166
AN XY:
625772
show subpopulations
African (AFR)
AF:
AC:
7608
AN:
29574
American (AMR)
AF:
AC:
7896
AN:
27410
Ashkenazi Jewish (ASJ)
AF:
AC:
4040
AN:
19504
East Asian (EAS)
AF:
AC:
451
AN:
33436
South Asian (SAS)
AF:
AC:
17780
AN:
65914
European-Finnish (FIN)
AF:
AC:
9586
AN:
29146
Middle Eastern (MID)
AF:
AC:
927
AN:
3598
European-Non Finnish (NFE)
AF:
AC:
286827
AN:
1027682
Other (OTH)
AF:
AC:
13747
AN:
53434
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.465
Heterozygous variant carriers
0
13293
26586
39880
53173
66466
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.269 AC: 39299AN: 146264Hom.: 5470 Cov.: 26 AF XY: 0.270 AC XY: 19150AN XY: 70948 show subpopulations
GnomAD4 genome
AF:
AC:
39299
AN:
146264
Hom.:
Cov.:
26
AF XY:
AC XY:
19150
AN XY:
70948
show subpopulations
African (AFR)
AF:
AC:
10717
AN:
39386
American (AMR)
AF:
AC:
3999
AN:
14494
Ashkenazi Jewish (ASJ)
AF:
AC:
721
AN:
3398
East Asian (EAS)
AF:
AC:
44
AN:
4732
South Asian (SAS)
AF:
AC:
1248
AN:
4406
European-Finnish (FIN)
AF:
AC:
3095
AN:
9774
Middle Eastern (MID)
AF:
AC:
70
AN:
282
European-Non Finnish (NFE)
AF:
AC:
18620
AN:
66886
Other (OTH)
AF:
AC:
513
AN:
2010
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1370
2740
4109
5479
6849
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
508
AN:
3474
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Jun 26, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.